Showing 4206 results for "als"

Filter By

Dazucorilant significantly extends survival in Phase 2 ALS trial

Dazucorilant, an oral cortisol modulator being developed by Corcept Therapeutics, significantly improved survival among people with amyotrophic lateral sclerosis (ALS) in a Phase 2 clinical trial. Despite it failing to slow disease progression, the trial’s main goal, Corcept is now seeking guidance from U.S. and European regulators to determine…

Finding comfort in AI: Using ChatGPT to cope with ALS grief

Someone in an online caregiver support group posted that they were finding value in using ChatGPT as a therapist. Other caregivers chimed in, saying they also turn to the artificial intelligence chatbot for support and find it surprisingly helpful. One person suggested prompting it to “respond like a counselor” or…

Ask the expert: Al Freedman on social isolation and ALS

Al Freedman, PhD, a psychologist who specializes in rare disease communities, discusses how to manage social isolation while living with amyotrophic lateral sclerosis (ALS). He shares his background as a father to his late son Jack, who had spinal muscular atrophy (SMA), and how his role as a caregiver has…

AMX0114 receives FDA fast track status for the treatment of ALS

The U.S. Food and Drug Administration (FDA) has granted fast track designation to AMX0114, an experimental therapy being developed by Amylyx Pharmaceuticals, for the treatment of amyotrophic lateral sclerosis (ALS). Fast track status is designed to facilitate the development and review of treatments that have the potential to address…